...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: a new study that one researcher called "stunning."

Chicagoest - RVX/Eversana are not capable of handling mfg, distribution, marketing, product liability & support for a blockbuster. 

Very good points. 40,000,000 patients is large.  We all get well with 30/40 SP.  For BP the potential is far to great to look the other way.  Hope we see a tax free tax over, allows time to liquidate.

Question to the forum, How many patients are  enrolled in the C19 P2?  Study called for 50/50.  We know first patient was dosed end of January.  Study was 28 days, correct?   Do we know?  With an Open Study  information should be available.  sidebar.

 

 

Share
New Message
Please login to post a reply